 AVEO Oncology Nasdaq: AVEO today announced that it has earned a 2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. Kyowa Kirin. The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug IND application for tivozanib in a non-oncology indication being developed by Kyowa Kirin. 